Siapati Elena K, Bigger Brian W, Miskin James, Chipchase Daniel, Parsley Kathryn L, Mitrophanous Kyriacos, Themis Mike, Thrasher Adrian J, Bonnet Dominique
Hematopoietic Stem Cell Laboratory, Cancer Research UK, 44 Lincoln's Inn Fields, London WC2A 3PX, UK.
Mol Ther. 2005 Sep;12(3):537-46. doi: 10.1016/j.ymthe.2005.01.022.
The use of lentiviral vectors for gene transfer into hematopoietic stem cells has raised considerable interest as these vectors can permanently integrate their genome into quiescent cells. Vectors based on alternative lentiviruses would theoretically be safer than HIV-1-based vectors and could also be used in HIV-positive patients, minimizing the risk of generating replication-competent virus. Here we report the use of third-generation equine infectious anemia virus (EIAV)- and HIV-1-based vectors with minimal viral sequences and absence of accessory proteins. We have compared their efficiency in transducing mouse and human hematopoietic stem cells both in vitro and in vivo to that of a previously documented second-generation HIV-1 vector. The third-generation EIAV- and HIV-based vectors gave comparable levels of transduction and transgene expression in both mouse and human NOD/SCID repopulating cells but were less efficient than the second-generation HIV-1 vector in human HSCs. For the EIAV vector this is possibly a reflection of the lower protein expression levels achieved in human cells, as vector copy number analysis revealed that this vector exhibited a trend to integrate equally efficiently compared to the third-generation HIV-1 vector in both mouse and human HSCs. Interestingly, the presence or absence of Tat in viral preparations did not influence the transduction efficiency of HIV-1 vectors in human HSCs.
将慢病毒载体用于基因转移至造血干细胞已引起了相当大的关注,因为这些载体能够将其基因组永久整合到静止细胞中。理论上,基于其他慢病毒的载体比基于HIV-1的载体更安全,并且也可用于HIV阳性患者,从而将产生具有复制能力病毒的风险降至最低。在此,我们报告了使用具有最少病毒序列且无辅助蛋白的第三代马传染性贫血病毒(EIAV)和基于HIV-1的载体。我们已将它们在体外和体内转导小鼠和人类造血干细胞的效率与先前记录的第二代HIV-1载体进行了比较。第三代基于EIAV和HIV的载体在小鼠和人类NOD/SCID重建造血细胞中产生了相当水平的转导和转基因表达,但在人类造血干细胞中比第二代HIV-1载体效率更低。对于EIAV载体,这可能反映了在人类细胞中实现的较低蛋白表达水平,因为载体拷贝数分析表明,与第三代HIV-1载体相比该载体在小鼠和人类造血干细胞中均呈现出同等高效整合的趋势。有趣的是,病毒制剂中Tat的存在与否并不影响HIV-1载体在人类造血干细胞中的转导效率。